Bayer develops the follow-up NOAC of Xarelto, strengthening its pipeline

Bayer has put much effort on the development of another new oral anticoagulant(NOAC).

According to the industry concerned on the 17^th, the new oral anticoagulant is a factor XI inhibitor unlike ‘Xarelto(rivaroxaban)’ inhibiting the coagulation factor X. Bayer is currently preparing for a Phase 2 clinical trial of its candidate sutstance ‘ISIS-FXIRx.’

ISIS-FXIRx is a substance purchased from I...